Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 24,612 |
|
|||||
| News | - | ||||||
| Day High | 2.59 | Low High |
|||||
| Day Low | 2.48 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cellectis SA | CLLS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0997 | -3.81% | 2.52 | 12:37:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.59 | 2.48 | 2.59 | 2.6197 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 73 | 24,612 | $ 2.48 | $ 61,102 | - | 0.962777 - 3.7735 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:46:01 | 1 | $ 2.52 | USD |
Cellectis SA Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 118.76M | 45.68M | - | 27.67M | -106.14M | -2.32 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cellectis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLLS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.51 | 2.65 | 2.30 | 2.58 | 20,896 | 0.01 | 0.40% |
| 1 Month | 2.53 | 2.95 | 2.30 | 2.64 | 33,194 | -0.01 | -0.40% |
| 3 Months | 2.92 | 3.13 | 2.30 | 2.69 | 36,813 | -0.40 | -13.70% |
| 6 Months | 1.12 | 3.7735 | 0.962777 | 2.74 | 983,258 | 1.40 | 125.00% |
| 1 Year | 1.89 | 3.7735 | 0.962777 | 2.70 | 514,527 | 0.63 | 33.33% |
| 3 Years | 19.31 | 20.42 | 0.962777 | 4.62 | 288,148 | -16.79 | -86.95% |
| 5 Years | 20.55 | 34.71 | 0.962777 | 9.56 | 254,575 | -18.03 | -87.74% |
Cellectis Description
| Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology. |
